The calendar is doing the heavy lifting for Bayer investors right now. A US appeals court cleared the path forward on August 27 for the company’s $7.25 billion Roundup settlement, setting the stage for a pivotal approval hearing on September 14. That date now anchors the near-term outlook for a stock that has climbed 71 percent over the past twelve months — a rally that suggests the market has already begun pricing in a resolution to the glyphosate litigation that has weighed on the German conglomerate for years.
The Eighth Circuit Court of Appeals rejected an attempt by settlement opponents to move the class action to federal court, removing one procedural hurdle that could have delayed the timeline. But the objectors’ underlying resistance to the settlement structure remains intact, leaving open the question of whether they will mount fresh challenges before the approval hearing. For shareholders, the key metric is no longer the share price itself but the procedural outcome: approved, postponed, or contested again.
UBS Sees Upside Beyond the Legal Fog
Against this legal backdrop, UBS reaffirmed its “Buy” rating on Bayer with a price target of EUR 62. The stock closed Friday at EUR 48.84, down 1.3 percent on the day, leaving substantial headroom to the bank’s target. The shares have been essentially flat over the past week, slipping 0.2 percent, and have lost 1.1 percent over the past month.
The UBS endorsement suggests the bank is increasingly valuing Bayer on operational fundamentals rather than litigation risk alone. That view finds support in the progress Bayer showcased at its agriculture investor day last Thursday, where the company reported that two of its ten planned new products — each with potential peak sales of at least EUR 500 million — have already been launched. Reuters noted specific introductions, including the Plenexos insecticide in Colombia and the Preceon corn variety across multiple markets.
Bayer also reaffirmed its medium-term targets for the Crop Science division: EBITDA growth of EUR 1 billion by the end of the decade, with margins advancing into the mid-twenties percentage range. The company pointed to nearly EUR 400 million in cost savings already realized, giving investors concrete milestones rather than mere promises.
A Tale of Two Divisions
The operational picture, however, is not uniformly bright. While the agriculture business delivered a 30.2 percent increase in adjusted earnings in the second quarter, the pharma division saw profits decline 3.6 percent over the same period. That divergence underscores a structural challenge: even with legal clarity on Roundup, Bayer’s growth story currently leans heavily on one pillar.
Should investors sell immediately? Or is it worth buying Bayer?
The pharma side does offer some counterpoints. Nubeqa, the cancer drug, generated quarterly sales of EUR 880 million in the second quarter of 2026, according to company figures. If legal certainty arrives alongside an accelerating product pipeline, the stock could benefit from dual tailwinds.
Reading the Technicals
The chart tells a story of measured optimism rather than euphoria. The stock trades roughly 17 percent above its 200-day moving average of EUR 41.76, indicating an intact long-term trend. Yet it sits about 9.3 percent below its 52-week high of EUR 53.86, suggesting some investor caution about a linear continuation of the rally.
With a relative strength index of 53 and a price hovering just above the 50-day average of EUR 48.67, the stock appears technically balanced — neither overbought nor oversold. That leaves room for movement in either direction as the September 14 hearing approaches.
The bearish scenario is less about the settlement collapsing entirely — the legal process has advanced too far for that — and more about delays and demands for modifications. Any additional challenges would postpone the legal certainty the market has been awaiting for months. The roughly 65,000 Roundup-related lawsuits that Reuters attributes to Bayer explain why every legal development draws close scrutiny, even when the immediate share price impact is muted.
For now, the path appears clear. If no new objections emerge before September 14, the conditions look favorable for court approval of the settlement, which would remove one of the largest remaining overhangs on Bayer’s stock. Should the picture shift — through new filings from settlement opponents or conditions imposed by the court — the uncertainty that has defined the stock for years could quickly resurface. The next concrete test is now clearly marked on the calendar.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from September 5 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 5.
Bayer: Buy or sell? Read more here...
